U.S. markets closed

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
29.44+1.85 (+6.71%)
At close: 4:00PM EDT

Pacific Biosciences of California, Inc.

1305 O’Brien Drive
Menlo Park, CA 94025
United States
650 521 8000
http://www.pacb.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees412

Key Executives

NameTitlePayExercisedYear Born
Mr. Christian O. Henry M.B.A.Pres, CEO & Director772.45kN/A1968
Ms. Susan G. KimChief Financial Officer238.87kN/A1977
Dr. Denis Zaccarin Ph.D.Sr. VP of R&D440.43kN/A1965
Dr. Stephen TurnerCo-Founder & CTON/AN/A1968
Mr. Mark Van OeneChief Operating OfficerN/AN/A1973
Ms. Michele FarmerVP & Chief Accounting OfficerN/AN/A1979
Dr. Jonas Korlach Ph.D.Chief Scientific OfficerN/AN/AN/A
Trevin RardHead of Investor RelationsN/AN/AN/A
Brett Atkins J.D., Ph.D.Gen. Counsel & Corp. Sec.N/AN/AN/A
Ms. Kathleen LynchHead of Global Gov. Affairs & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Corporate Governance

Pacific Biosciences of California, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 5. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.